-+ 0.00%
-+ 0.00%
-+ 0.00%

SciSparc unit NeuroThera wins conditional TSX approval for CliniQuantum acquisition update

PUBT·05/28/2026 12:40:14
Listen to the news
SciSparc unit NeuroThera wins conditional TSX approval for CliniQuantum acquisition update
  • SciSparc subsidiary NeuroThera Labs received conditional TSX Venture Exchange clearance to buy about 54% of CliniQuantum.
  • NeuroThera plans to issue 56,600,000 common shares valued at about $9.46 million to acquire 56,375 CliniQuantum shares.
  • The deal’s outside date was extended to June 1, 2026, pending an Israeli tax ruling and final TSX acceptance.
  • Earn-out shares will be priced at no less than $0.05 each, with a floor price and seller lock-ups added to the terms.
  • All 56,600,000 consideration shares will be placed in escrow under a Form 5D escrow agreement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605280840PRIMZONEFULLFEED9728146) on May 28, 2026, and is solely responsible for the information contained therein.